Magle Chemoswed (MAGLE) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 net sales were SEK 70.9m; EBIT was SEK -45.0m and net result after tax SEK -107.1m, with results affected by non-recurring items.
Directed share issues, set-off issues and bond refinancing increased equity and cash; liabilities to credit institutions were repaid.
Financial highlights
Q3 net sales SEK 70.9m vs SEK 71.5m; 9M net sales SEK 212.4m vs SEK 205.2m, up 3.5%.
Q3 EBIT SEK -45.0m vs SEK 20.3m; EBITDA SEK -31.1m vs SEK 33.4m; net result after tax SEK -107.1m vs SEK 3.1m.
9M EBIT SEK -75.8m vs SEK -6.6m; EBITDA SEK -36.1m vs SEK 31.6m; net result after tax SEK -146.1m vs SEK -25.8m.
Key financial ratios and metrics
Cash and cash equivalents were SEK 38.7m at Sep 30, 2026, vs SEK 2.1m at Jun 30, 2026.
Shareholders’ equity was SEK 320.4m; equity ratio 38.0% vs 36.5% at Dec 31, 2025.
Latest events from Magle Chemoswed
- Revenue up but losses and tight liquidity persist; recapitalization and delisting planned.MAGLE
Q2 2026 - Revenue fell and losses deepened in Q1 2026 amid restructuring and operational challenges.MAGLE
Q1 2026 - Major asset write-downs and negative results in Q4 2025 prompt capital raises and restructuring.MAGLE
Q4 2025 - Q3 2025 delivered stronger EBITDA and integration progress, offset by Biopharma market weakness.MAGLE
Q3 2025 - Revenue up but profitability down in Q2 2025; integration and supply chain issues impacted results.MAGLE
Q2 2025 - Strong Q3 growth driven by mergers, robust CDMO demand, and one-off PPA income.MAGLE
Q3 2024 - Q2 sales up 17% as Magle Group advances major mergers to drive future growth.MAGLE
Q2 2024 - Q1 2025 revenue surged, but integration costs led to a net loss as acquisitions drive future growth.MAGLE
Q1 2025 - Strong revenue growth and strategic acquisitions drive Magle Group's 2024 performance.MAGLE
Q4 2024